Galia Nordon, Ph.D. Thesis Seminar
For password to lecture, please contact: email@example.com
Advisor: rof. B. Kimelfeld, Dr. K. Radinsky, Prof. V. Shalev
Drug repurposing is the process of applying known drugs to treat new diseases. Successful repurposing can reduce costs and time to market as medications have already passed studies of human safety. It is an important task due to the length of time and the large cost of novel drug development. In recent years, alongside the growing resources needed for developing new drugs, large biomedical repositories are becoming available as well as the maturing technology for analyzing them. These factors make the task of drug repurposing a relevant and important one.
In this thesis we address the task of drug repurposing using three data modalities: (1) Electronic Health Records collected for over 10 years for over 2 million patients. (2) Biomedical literature consisting of over 28 million publications. (3) The chemical structure of the drug compound.
These modalities are complementary as each of them provides a different kind of information. Electronic health records hold comprehensive observational data, biomedical literature holds theoretical knowledge, and the chemical structure describes the fundamental properties of the drug.
We describe the results obtained from analyzing electronic health records, regarding the task of drug re-purposing for Hypertension and Type II Diabetes as well as consequent discoveries made regrading the effects of beta-blockers on Parkinson's morbidity. We discuss the challenges in such an analysis and continue to demonstrate how combining literature knowledge may aid this task. We further build a medical-condition causal graph based on these two repositories.
We then demonstrate the use of the chemical structure modality: alone, for the task of lead optimization, and combined with biomedical literature, for the task of embedding drugs in a vector space. We show the embedding we obtain is useful in predicting drug repurposing.